SINTX Technologies Q3 2026 revenue jumps to $2.19M
A post-quarter exercise of 941,423 Class B warrants generated approximately $2.0 million in gross proceeds at $2.14 per share.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
SINTX Technologies, Inc. reported third-quarter 2026 revenue of $2.190 million, compared with $208,000 a year earlier; gross profit was $1.362 million versus $93,000, and gross margin was 62% versus 45%. Operating expenses were $2.997 million, compared with $3.448 million, while operating loss decreased to $1.635 million from $3.355 million and net loss to $1.595 million from $3.539 million. For the first nine months of 2026, revenue was $3.022 million, up 315%.
Cash and cash equivalents were $2.005 million as of September 30, 2026, compared with $4.140 million as of December 31, 2025. After quarter-end, SINTX received approximately $2.0 million in gross proceeds from 941,423 Class B warrant exercises at $2.14 per share, following achievement of a $2 million third-quarter revenue milestone. The company completed a limited-use release of its FDA-cleared SiNAPTIC Foot & Ankle Osteotomy Wedge System, with initial commercial sales underway, and regained compliance with Nasdaq’s $2.5 million minimum stockholders’ equity requirement. Large-animal studies of treated medical textiles are expected to be completed in the first quarter of 2027.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Positive
- Moderate pointThird-quarter revenue reached $2.190 million, versus $208,000 a year earlier.
- Moderate pointOperating loss decreased 51% to $1.635 million year over year.
- Minor pointNet loss decreased 55% to $1.595 million year over year.
Negative
- None.
Filing Explained
The November 5 Form 8-K reports SINTX’s third-quarter cash position: at
Sources and calculations
- SINTX Technologies Form 8-K and Exhibit 99.1 (2026-11-05)
- SINTX third-quarter 2026 fundamentals (2026Q3)
- Available liquidity against the last reported quarterly operating outflow, in days at that rate $2,005,000 / ($1,369,000 / 92) = 134.7 days
8-K Event Classification
Key Figures
Key Terms
gross margin financial
Class B warrants financial
limited-use release technical
in vivo studies medical
minimum stockholders’ equity requirement regulatory
Earnings Snapshot
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How much revenue did SINT report in Q3 2026?
How much did SINTX receive from its Class B warrant exercises?
What are SINT’s wound-care studies evaluating?
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
(Address of principal executive offices, including Zip Code)
Registrant’s
telephone number, including area code:
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class: | Trading Symbol(s): | Name of each exchange on which registered: | ||
| The
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging
growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On November 5, 2026, SINTX Technologies, Inc. (the “Company”) issued a press release providing a business update in connection with the filing of its Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, including certain information regarding the Company’s results of operations, financial condition and revenue outlook. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Item 7.01. Regulation FD Disclosure.
The information contained in the press release furnished as Exhibit 99.1 also includes updates regarding the Company’s commercialization activities, customer purchase orders, product-development programs, strategic initiatives and other business matters.
The information furnished pursuant to Items 2.02 and 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
| Exhibit No. | Description | |
| 99.1 | Press Release dated November 5, 2026 | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| SINTX Technologies, Inc. | ||||
| Date: | November 5, 2026 | By: | /s/ Kevin Trask | |
| Kevin Trask | ||||
| Chief Financial Officer | ||||
Exhibit 99.1
SINTX Reports Record Third Quarter 2026 Revenue Growth and Advances Medical Device Commercialization
Third quarter revenue increases more than tenfold year over year, while operating losses decrease 51% as Company advances commercialization of its proprietary silicon nitride technologies
SALT LAKE CITY, Utah – November 5, 2026 – SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), a global leader in advanced silicon nitride biomaterials and ceramics for medical and industrial applications, today announced its financial results and business highlights for the third quarter ended September 30, 2026.
Third Quarter Financial Results
| ● | For the three months ended September 30, 2026, total revenue increased to approximately $2.2 million, compared with $208,000 during the prior-year period | |
| ● | Gross profit increased to approximately $1.4 million, compared with $93,000 in the prior-year quarter, with gross margin increasing to approximately 62% from 45% reflecting improved pricing, higher manufacturing volumes, and increased production efficiencies | |
| ● | Total operating expenses decreased 13% to $3.0 million, compared with $3.4 million in the third quarter of 2025 | |
| ● | Net loss decreased 55% to approximately $1.6 million, compared with $3.5 million during the prior-year quarter | |
| ● | Operating loss decreased 51% to $1.6 million, compared with $3.4 million in the third quarter of 2025 | |
| ● | For the nine months ended September 30, 2026, total revenue increased 315% to approximately $3.0 million | |
| ● | SINTX ended the third quarter with approximately $2.0 million in cash and cash equivalents and subsequently received approximately $2.0 million in gross proceeds from the exercise of Class B warrants. The Company continues to pursue revenue growth, operating efficiencies, and additional financing alternatives to support operations and commercialization activities. |
“Our third-quarter results represent a meaningful milestone in the commercial transformation of SINTX Technologies,” said Eric Olson, Chief Executive Officer of SINTX.
“The substantial increase in quarterly revenue, combined with significant improvements in gross profit and operating performance, demonstrates the potential of our advanced manufacturing platform as we convert investments over the past several years into revenue-building commercial opportunities. Our industrial business is providing an important commercial foundation as we pursue what we believe are even greater long-term opportunities in healthcare.
“With the initial commercial sales of our SiNAPTIC® Foot & Ankle Osteotomy Wedge System underway, we have established a foundation for expanding our presence in the orthopedic implant market. We also continue to evaluate opportunities to leverage our proprietary silicon nitride technology in spinal applications, next-generation orthopedic implants, advanced composites, and antipathogenic medical technologies such as wound care and wound dressing applications.
“We believe our performance this quarter demonstrates measurable progress toward building a commercially focused advanced materials company. With improving operating performance, expanding commercial activities, and continued investment in our proprietary technologies, we believe SINTX is well positioned to pursue additional growth opportunities in 2027,” concluded Mr. Olson.
Third Quarter and Subsequent 2026 Highlights
| ● | Completed the limited-use release of the FDA-cleared SiNAPTIC Foot & Ankle Osteotomy Wedge System, initiated in the first quarter of 2026 | |
| ● | Sponsored silicon nitride masterclass with leading orthopedics experts in implant retrieval, biomaterials and clinical practice, to help educate surgeons, develop sales channels and build a disciplined commercial foundation | |
| ● | Regained compliance with Nasdaq’s minimum stockholders’ equity requirement of $2.5 million | |
| ● | Received aggregate gross proceeds of approximately $2.0 million from the exercise of 941,423 Class B warrants at $2.14 per share following the Company’s post-quarter-end call, which was triggered by achieving the third-quarter revenue milestone of $2 million. | |
The Company will host a conference call and webcast today at 4:30 p.m. ET to review the Company’s third quarter 2026 performance. Management participants will include Eric Olson, Chief Executive Officer and Chairman of the Board, and Kevin Trask, Chief Financial Officer.
Interested parties may access the conference call and webcast as follows:
Webcast: The live webcast will be available on the Events & Presentations page of the Company’s investor relations website at investors.sintx.com and may also be accessed directly here.
Telephone: Analysts and other participants who wish to join by telephone should register in advance using the Conference Call Registration link. Upon registration, participants will receive the dial-in information and a unique PIN.
A replay of the webcast will be available following the call on the Events & Presentations page of the Company’s investor relations website.
About SINTX Technologies, Inc.
Headquartered in Salt Lake City, Utah, SINTX Technologies, Inc. (NASDAQ: SINT) is an advanced biomaterials company that develops, manufactures, and commercializes patented and proprietary silicon nitride ceramic biomaterials, composites, devices, and related ceramics technologies for medical and other specialized industrial applications. SINTX has 20 years of experience innovating silicon nitride technologies and operates under a quality management system certified to ISO 13485:2016 and AS9100D, with a product portfolio that includes insulators for Tier 1 aerospace suppliers, the FDA-cleared SiNAPTIC® Foot & Ankle Osteotomy Wedge System for reconstructive surgery, OEM manufacturing of FDA-cleared spinal implants, and its SiNERGY™ technology platform being developed for biocomposite and 3D printing applications.
Forward-Looking Statements
Company Contact:
Andrew Benson
SINTX Technologies, Inc.
801.839.3500
IR@sintx.com
SINTX Technologies, Inc.
Condensed Consolidated Balance Sheets – Unaudited
(in thousands, except share and per-share amounts)
September 30, 2026 | December 31, 2025 | |||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 2,005 | $ | 4,140 | ||||
| Accounts and other receivables, net of allowance for credit losses of $2.0 and $2.4 respectively | 131 | 178 | ||||||
| Prepaid expenses and other current assets | 829 | 507 | ||||||
| Inventories | 2,555 | 825 | ||||||
| Total current assets | 5,520 | 5,650 | ||||||
| Inventories | - | 219 | ||||||
| Property and equipment, net | 518 | 476 | ||||||
| Intangible assets, net | 116 | 142 | ||||||
| Goodwill | 302 | 302 | ||||||
| Operating lease right of use asset | 2,213 | 2,458 | ||||||
| Other long-term assets | 234 | 259 | ||||||
| Total assets | $ | 8,903 | $ | 9,506 | ||||
| Liabilities and Stockholders’ Equity | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 961 | $ | 382 | ||||
| Accrued liabilities | 1,190 | 422 | ||||||
| Debt | 55 | 7 | ||||||
| Derivative liabilities | 345 | 827 | ||||||
| Current portion of operating lease liability | 440 | 398 | ||||||
| Other current liabilities | 13 | 1,697 | ||||||
| Total current liabilities | 3,004 | 3,733 | ||||||
| Operating lease liability, net of current portion | 2,509 | 2,844 | ||||||
| Total liabilities | 5,513 | 6,577 | ||||||
| Commitments and contingencies | ||||||||
| Stockholders’ equity: | ||||||||
| Convertible preferred stock Series B, C, D, $0.01 par value, 130,000,000 total shares authorized inclusive of all series of preferred; 249 total preferred shares issued and outstanding as of September 30, 2026 and December 31, 2025. | - | - | ||||||
| Common stock, $0.01 par value, 250,000,000 shares authorized; 6,937,357 and 4,021,293 shares issued and 6,886,933 and 3,970,869 outstanding as of September 30, 2026 and December 31, 2025, respectively. | 69 | 40 | ||||||
| Treasury Stock, 50,424 shares as of September 30, 2026 and December 31, 2025. | (133 | ) | (133 | ) | ||||
| Additional paid-in capital | 302,678 | 295,124 | ||||||
| Accumulated deficit | (299,224 | ) | (292,102 | ) | ||||
| Total stockholders’ equity | 3,390 | 2,929 | ||||||
| Total liabilities and stockholders’ equity | $ | 8,903 | $ | 9,506 | ||||
SINTX Technologies, Inc.
Condensed Consolidated Statements of Operations – Unaudited
Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Product revenue | $ | 2,090 | $ | 150 | $ | 2,837 | $ | 541 | ||||||||
| Grant and contract revenue | 100 | 58 | 185 | 187 | ||||||||||||
| Total revenue | 2,190 | 208 | 3,022 | 728 | ||||||||||||
| Costs of revenue | 828 | 115 | 1,238 | 455 | ||||||||||||
| Gross profit | 1,362 | 93 | 1,784 | 273 | ||||||||||||
| Operating expenses: | ||||||||||||||||
| Research and development | 548 | 1,264 | 1,485 | 3,618 | ||||||||||||
| General and administrative | 2,251 | 2,102 | 7,104 | 4,836 | ||||||||||||
| Sales and marketing | 140 | 59 | 812 | 100 | ||||||||||||
| Grant and contract expenses | 58 | 23 | 113 | 122 | ||||||||||||
| Total operating expenses | 2,997 | 3,448 | 9,514 | 8,676 | ||||||||||||
| Loss from operations | (1,635 | ) | (3,355 | ) | (7,730 | ) | (8,403 | ) | ||||||||
| Other income (expenses): | ||||||||||||||||
| Interest expense | (2 | ) | (13 | ) | (16 | ) | (40 | ) | ||||||||
| Interest income | 11 | 43 | 45 | 130 | ||||||||||||
| Gain on disposal of equipment | - | - | - | 327 | ||||||||||||
| Change in fair value of derivative liabilities | - | (214 | ) | 482 | (166 | ) | ||||||||||
| Other income, net | 31 | - | 97 | 3 | ||||||||||||
| Total other income (expense), net | 40 | (184 | ) | 608 | 254 | |||||||||||
| Net loss before income taxes | (1,595 | ) | (3,539 | ) | (7,122 | ) | (8,149 | ) | ||||||||
| Provision for income taxes | - | - | - | - | ||||||||||||
| Net loss | $ | (1,595 | ) | $ | (3,539 | ) | $ | (7,122 | ) | $ | (8,149 | ) | ||||
| Deemed dividend – warrant modification | - | - | (926 | ) | - | |||||||||||
| Deemed dividend – warrant inducement | - | (6,719 | ) | - | (6,719 | ) | ||||||||||
| Net loss attributable to common stockholders | $ | (1,595 | ) | $ | (10,258 | ) | $ | (8,048 | ) | $ | (14,868 | ) | ||||
| Net loss per share – basic and diluted | ||||||||||||||||
| Basic – net loss | $ | (0.24 | ) | $ | (1.19 | ) | $ | (1.37 | ) | $ | (3.38 | ) | ||||
| Basic – attributable to common stockholders | $ | (0.24 | ) | $ | (3.46 | ) | $ | (1.55 | ) | $ | (6.17 | ) | ||||
| Diluted – net loss | $ | (0.24 | ) | $ | (1.19 | ) | $ | (1.37 | ) | $ | (3.38 | ) | ||||
| Diluted – attributable to common stockholders | $ | (0.24 | ) | $ | (3.46 | ) | $ | (1.55 | ) | $ | (6.17 | ) | ||||
| Weighted average common shares outstanding: | ||||||||||||||||
| Basic | 6,665,926 | 2,963,539 | 5,186,059 | 2,411,004 | ||||||||||||
| Diluted | 6,665,926 | 2,963,539 | 5,186,570 | 2,411,179 | ||||||||||||